Markets

Insider Trading

Hedge Funds

Retirement

Opinion

10 Best Innovative Stocks that Pay Dividends

Page 1 of 8

In this article, we will discuss the best innovative stocks that pay dividends.

Innovation plays a crucial role in today’s market. With the significant attention tech stocks have gained over the past year, it’s clear where investors are directing their funds. Tech firms are leveraging disruptive technologies like artificial intelligence to process vast, complex datasets. In the healthcare sector, advancements in research and development (R&D) have led to life-saving drug therapies and treatments. Meanwhile, the growing impact of climate change is pushing energy and utility companies to prioritize renewable energy sources. Therefore, innovation lies at the heart of every industry today.

Businesses in the US and globally swiftly recognized the influence of innovation on their growth and operations, and they are gradually shaping their activities around it. A recent McKinsey survey of over 1,000 executives revealed that companies with a strong culture of innovation are twice as successful as some of their peers in scaling digital transformations. These innovative firms focus on technologies and changes to their operating models that promote rapid learning and adaptation—essential components of innovation. The report also highlighted that 14 of the top 20 global companies have leveraged innovation to either expand existing markets or create entirely new ones.

Read also: Top 18 Automotive Industry Innovations and Trends

A key component of innovation is R&D, which focuses on systematic and scientific investigation to create new products, technologies, or processes. Through R&D investments, companies can strengthen their abilities, explore fresh ideas, and discover innovative solutions to address customer demands. Businesses worldwide, particularly in the pharmaceutical sector, have boosted their R&D investments to develop new products that meet the demands of their customers. Financial Times reported that R&D in the US has grown in recent decades, increasing from 2.2% of GDP in the 1980s to 3.4% in 2021. This rise is mainly due to the private sector’s contribution, which doubled to 2.5% of GDP. Moreover, the percentage of the population involved in patent creation almost doubled during this time.

It’s not just established companies that are embracing innovation in their operations; the rise of US startups also reflects this trend, as they introduce groundbreaking business ideas previously unheard of. Economist John Haltiwanger found that Americans were starting new businesses at an unprecedented rate. And he’s not mistaken. In 2020, more new businesses were launched than in any previous year, with 2021 following closely behind. According to the Kauffman Indicators of Entrepreneurship, the one-year survival rate for these startups exceeded 80% in 2021, marking the highest rate since 1999. Haltiwanger noted that a surge in new businesses is a strong indicator of job creation, innovation, and productivity growth within the economy. He further said that startup booms not only reflect technological innovation but also significantly drive it. Startups explore how to leverage new technologies, experiment with them, and create new products, pushing competitors to adapt and innovate in response. Research from Texas McCombs, which examined 6,116 patents from the mid-1970s to 2016, highlighted the impact of startups on innovation. The study found that patents from startups were cited 8.5% more each year and 21% more over a nine-year period compared to patents from established companies. With this, we will now take a look at some of the best innovative stocks that pay dividends.

SFIO CRACHO/Shutterstock.com

Our Methodology:

For this article, we scanned Insider Monkey’s database of 912 hedge funds as of Q2 2024 and picked companies that actively prioritize and promote the development of new and groundbreaking ideas, products, services, or business processes. From that list, we picked 10 stocks with the highest number of hedge fund investors and ranked them in ascending order of hedge funds’ sentiment towards them. These companies belong to different sectors, including healthcare, technology, aerospace, and defense.

Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 275% since May 2014, beating its benchmark by 150 percentage points. (see more details here).

10. Caterpillar Inc. (NYSE:CAT)

Number of Hedge Fund Holders: 49

Caterpillar Inc. (NYSE:CAT) is an American company that specializes in construction, mining, and other engineering equipment. In the early 20th century, the company developed the first effective track-type tractor, commonly referred to as a crawler. This innovation transformed earthmoving and construction machinery by offering improved traction and maneuverability on difficult terrains. It is among the best innovative stocks that pay dividends.

Caterpillar Inc. (NYSE:CAT) has jumped almost 21% since the beginning of 2024, driven by its involvement in several new economic trends. These include the shift towards energy transition and its effect on the company’s sales, as well as its adoption of technology—such as e-commerce and digital tools—to boost its more stable services revenue. In addition, the company is also benefitting from the housing market. Diamond Hill Capital also highlighted this in its Q1 2024 investor letter. Here is what the firm has to say:

“Other top contributors included Allstate, Caterpillar Inc. (NYSE:CAT) and General Motors. Shares of heavy construction machinery manufacturer Caterpillar benefited from a positive US housing market, which despite rising interest rates, is seeing strong demand in the face of relatively short housing supply.”

Caterpillar Inc. (NYSE:CAT) is also a strong company from a dividend point of view. In the second quarter of 2024, the company reported an enterprise operating cash flow of $3 billion. Moreover, it ended the quarter with $4.3 billion available in cash. The company remained committed to its shareholder obligation, returning $0.6 billion to investors through dividends during the quarter.

On June 12, Caterpillar Inc. (NYSE:CAT) declared an 8.5% hike in its quarterly dividend to $1.41 per share. Through this increase, the company stretched its dividend growth streak to 30 years, which makes CAT one of the best innovative dividend stocks on our list. The stock has a dividend yield of 1.60%, as of September 18.

The number of hedge funds tracked by Insider Monkey owning stakes in Caterpillar Inc. (NYSE:CAT) grew to 49 in Q2 2024, from 45 in the previous quarter. These stakes have a total value of $6.4 billion. Among these hedge funds, Fisher Asset Management was the company’s leading stakeholder in Q2.

9. Honeywell International Inc. (NASDAQ:HON)

Number of Hedge Fund Holders: 50

Honeywell International Inc. (NASDAQ:HON) is a North Carolina-based company that offers customers in a wide range of industries. The company developed the thermostatic expansion valve (TXV), a component used in refrigeration and air conditioning systems. The TXV controls the flow of refrigerant, helping to maintain the correct temperature and pressure, which enhances the efficiency of cooling systems. The stock is down by over 3% since the start of 2024 because its industrial automation sector saw a decline. This downturn reflects customers’ reluctance to make new investments amid the current economic uncertainty.

However, in the second quarter of 2024, Honeywell International Inc. (NASDAQ:HON) reported strong earnings, consistently meeting or surpassing its guidance across all metrics despite navigating a dynamic operating environment. While Aerospace remains a key driver of growth, the company observed broader contributions from its portfolio, with three out of four segments showing positive growth for the quarter. Additionally, all four segments experienced sequential growth, reinforcing confidence in the anticipated acceleration of organic growth in the second half of the year.

Investors are also inclined to Honeywell International Inc. (NASDAQ:HON) because of its cash position and its consistent progress in capital deployment strategy. In the most recent quarter, the company reported an operating cash flow of $1.4 billion and its free cash flow came in at $1.1 billion. In addition, it allocated $6.4 billion towards mergers and acquisitions, dividends, share repurchases, and capital expenditures, including the completion of its $5 billion acquisition of Access Solutions.

Honeywell International Inc. (NASDAQ:HON), one of the best innovative stocks that pay dividends, has raised its payouts 14 times in the past 13 consecutive years. The company’s quarterly dividend currently sits at $1.08 per share for a dividend yield of 2.14%, as of September 18.

At the end of Q2 2024, 50 hedge funds tracked by Insider Monkey reported having stakes in Honeywell International Inc. (NASDAQ:HON), compared with 52 in the previous quarter. These stakes have a consolidated value of over $1.07 billion.

8. Texas Instruments Incorporated (NASDAQ:TXN)

Number of Hedge Fund Holders: 50

Texas Instruments Incorporated (NASDAQ:TXN) is an American multinational semiconductor company that produces analog and embedded chips. The company is recognized for creating the first commercial silicon transistor in 1954, a breakthrough that transformed the electronics industry. They were also early innovators in integrated circuit development, often referred to as chips or microchips. TI’s integrated circuits were essential in reducing the size of electronic components and advancing modern computing and communication technologies. Additionally, the company launched the first handheld electronic calculator, the TI-2500, in 1967. It is among the best innovative stocks that pay dividends.

The analog chip industry is facing one of its most significant downturns, and Texas Instruments Incorporated (NASDAQ:TXN) is struggling to manage this difficult period. Despite the challenges, the company is making progress with its resources. Over the past year, it has invested $3.7 billion in research and development (R&D) and selling, general, and administrative expenses (SG&A), spent $5.0 billion on capital expenditures, and returned $4.9 billion to shareholders. The company has also updated its forecasts for free cash flow per share under different recovery scenarios for 2026, projecting a range of $8 to $12. Its strong track record of cash flow and dividend growth continues to make it a solid long-term investment.

In the second quarter of 2024, Texas Instruments Incorporated (NASDAQ:TXN) generated $1.6 billion in operating cash flow and its free cash flow was $507 million. The company returned over $1.1 billion to shareholders through dividends. In addition to its commitment to shareholder return, Texas Instruments also practices dividend growth. The company’s dividend growth streak currently spans over 12 years. It pays a per-share dividend of $1.30 every quarter and has a dividend yield of 2.57%, as of September 18.

As of the close of Q2 2024, 50 hedge funds owned stakes in Texas Instruments Incorporated (NASDAQ:TXN), up from 49 in the previous quarter, as per Insider Monkey’s database. These stakes are collectively valued at over $2.7 billion. With over 4.2 million shares, First Eagle Investment Management was the company’s leading stakeholder in Q2.

Page 1 of 8

AI Fire Sale: Insider Monkey’s #1 AI Stock Pick Is On A Steep Discount

Artificial intelligence is the greatest investment opportunity of our lifetime. The time to invest in groundbreaking AI is now, and this stock is a steal!

The whispers are turning into roars.

Artificial intelligence isn’t science fiction anymore.

It’s the revolution reshaping every industry on the planet.

From driverless cars to medical breakthroughs, AI is on the cusp of a global explosion, and savvy investors stand to reap the rewards.

Here’s why this is the prime moment to jump on the AI bandwagon:

Exponential Growth on the Horizon: Forget linear growth – AI is poised for a hockey stick trajectory.

Imagine every sector, from healthcare to finance, infused with superhuman intelligence.

We’re talking disease prediction, hyper-personalized marketing, and automated logistics that streamline everything.

This isn’t a maybe – it’s an inevitability.

Early investors will be the ones positioned to ride the wave of this technological tsunami.

Ground Floor Opportunity: Remember the early days of the internet?

Those who saw the potential of tech giants back then are sitting pretty today.

AI is at a similar inflection point.

We’re not talking about established players – we’re talking about nimble startups with groundbreaking ideas and the potential to become the next Google or Amazon.

This is your chance to get in before the rockets take off!

Disruption is the New Name of the Game: Let’s face it, complacency breeds stagnation.

AI is the ultimate disruptor, and it’s shaking the foundations of traditional industries.

The companies that embrace AI will thrive, while the dinosaurs clinging to outdated methods will be left in the dust.

As an investor, you want to be on the side of the winners, and AI is the winning ticket.

The Talent Pool is Overflowing: The world’s brightest minds are flocking to AI.

From computer scientists to mathematicians, the next generation of innovators is pouring its energy into this field.

This influx of talent guarantees a constant stream of groundbreaking ideas and rapid advancements.

By investing in AI, you’re essentially backing the future.

The future is powered by artificial intelligence, and the time to invest is NOW.

Don’t be a spectator in this technological revolution.

Dive into the AI gold rush and watch your portfolio soar alongside the brightest minds of our generation.

This isn’t just about making money – it’s about being part of the future.

So, buckle up and get ready for the ride of your investment life!

Act Now and Unlock a Potential 10,000% Return: This AI Stock is a Diamond in the Rough (But Our Help is Key!)

The AI revolution is upon us, and savvy investors stand to make a fortune.

But with so many choices, how do you find the hidden gem – the company poised for explosive growth?

That’s where our expertise comes in.

We’ve got the answer, but there’s a twist…

Imagine an AI company so groundbreaking, so far ahead of the curve, that even if its stock price quadrupled today, it would still be considered ridiculously cheap.

That’s the potential you’re looking at. This isn’t just about a decent return – we’re talking about a 10,000% gain over the next decade!

Our research team has identified a hidden gem – an AI company with cutting-edge technology, massive potential, and a current stock price that screams opportunity.

This company boasts the most advanced technology in the AI sector, putting them leagues ahead of competitors.

It’s like having a race car on a go-kart track.

They have a strong possibility of cornering entire markets, becoming the undisputed leader in their field.

Here’s the catch (it’s a good one): To uncover this sleeping giant, you’ll need our exclusive intel.

We want to make sure none of our valued readers miss out on this groundbreaking opportunity!

That’s why we’re slashing the price of our Premium Readership Newsletter by a whopping 70%.

For a ridiculously low price of just $29, you can unlock a year’s worth of in-depth investment research and exclusive insights – that’s less than a single restaurant meal!

Here’s why this is a deal you can’t afford to pass up:

• Access to our Detailed Report on this Game-Changing AI Stock: Our in-depth report dives deep into our #1 AI stock’s groundbreaking technology and massive growth potential.

• 11 New Issues of Our Premium Readership Newsletter: You will also receive 11 new issues and at least one new stock pick per month from our monthly newsletter’s portfolio over the next 12 months. These stocks are handpicked by our research director, Dr. Inan Dogan.

• One free upcoming issue of our 70+ page Quarterly Newsletter: A value of $149

• Bonus Reports: Premium access to members-only fund manager video interviews

• Ad-Free Browsing: Enjoy a year of investment research free from distracting banner and pop-up ads, allowing you to focus on uncovering the next big opportunity.

• 30-Day Money-Back Guarantee:  If you’re not absolutely satisfied with our service, we’ll provide a full refund within 30 days, no questions asked.

 

Space is Limited! Only 1000 spots are available for this exclusive offer. Don’t let this chance slip away – subscribe to our Premium Readership Newsletter today and unlock the potential for a life-changing investment.

Here’s what to do next:

1. Head over to our website and subscribe to our Premium Readership Newsletter for just $29.

2. Enjoy a year of ad-free browsing, exclusive access to our in-depth report on the revolutionary AI company, and the upcoming issues of our Premium Readership Newsletter over the next 12 months.

3. Sit back, relax, and know that you’re backed by our ironclad 30-day money-back guarantee.

Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future!


No worries about auto-renewals! Our 30-Day Money-Back Guarantee applies whether you’re joining us for the first time or renewing your subscription a year later!

Penicillin Changed the World. This Drug Could Too

This Clinical-stage Biotech Company is Taking a Revolutionary Approach to Eradicating Many Respiratory Viruses Including a single drug to treat COVID, RSV, FLU and even Monkey-pox!

This is a clinical-stage, global leader in broad-spectrum antiviral nanomedicines who is developing therapeutic drugs that work safely and effectively, even against emerging variants!

A novel broad-spectrum antiviral

NV-387,  a drug that  treats RSV, COVID-19, Long COVID, Influenza, Bird Flu H5N1, and other respiratory viral infections as well as Monkey-pox, has successfully completed Phase 1 clinical trials in healthy subjects with no reported adverse events, even at the highest and repeated dosages. Remarkably, the company has been able to develop NV-387 for oral administration already, as well as for injectable and inhalation formulations to enable many modes of use. The Company is currently focused on advancing NV-387 into Phase II human clinical trials for the treatment of RSV infection.

Susceptible viruses CANNOT escape NV-387, even as they continue to evolve in the field into variants. Why? Because  no matter how much the virus changes, it continues to use the same host-side signature to bind to and cause infection in the hosts, and thus the nanoviricide would be anticipated to continue to be effective even as the virus mutates to generate variants.

Click to continue reading…